Online Support Tool Tested for Quality of Life in Multiple Myeloma
Tests a personalized web-based support platform in people with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Digital Support for Multiple Myeloma Quality of Life
Key facts
- Where
- Athens, GreeceSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed or relapsed/refractory multiple myeloma who can use a digital platform or app. It studies web-based support for quality of life.
- Age
- Adults (no exact age range given)
- Sex
- All sexes can join.
- Disease stage
- Newly diagnosed multiple myeloma, or multiple myeloma that came back or did not respond to treatment (relapsed/refractory).
Main reasons for not taking part
- Patients who are not able to use the digital platform or application
Read by machine on 13 November 2026.
Where in Greece
- Alexandra General HospitalAthens, GreeceContact: Professor Evangelos TerposTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- CareAcross
- Trial code
- NCT07642362
- Record updated
- 11 June 2026
- Original description
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.Read full original descriptionShow less
Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)
The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.
Specifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.
Inclusion: Adult patients with newly diagnosed or relapsed/refractory multiple myeloma; Patients that are able to use the digital platform/application.
Exclusion: Patients that are not able to use the digital platform/application.